Concepedia

Natnaree Siriwon

NS

Statistics

Publications

13

Citations

1.3K

H-Index

13

Active since

2014

Affiliations

University of Southern California(Current)

Oregon Health & Science University

PDX Pharmaceuticals (United States)

Shanghai CASB Biotechnology (China)

Natnaree Siriwon is an author at University of Southern California specializing in oncology, drug delivery, and targeted cancer therapy.

Publications per year

2014–2025

13

Publications

13

Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors

Si Li, Natnaree Siriwon, Xiaoyang Zhang et al. · Clinical Cancer Research · 2017 · 300 citations · Full text

, , +17

Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

Moataz Reda, Worapol Ngamcherdtrakul, Molly A. Nelson et al. · Nature Communications · 2022 · 189 citations · Full text

, , +17

CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction

Natnaree Siriwon, Elizabeth L. Siegler, Xianhui Chen et al. · Cancer Immunology Research · 2018 · 164 citations

, , +17

Masked Chimeric Antigen Receptor for Tumor-Specific Activation

Xiaolu Han, Paul D. Bryson, Yifan Zhao et al. · Molecular Therapy · 2017 · 115 citations · Full text

, , +17

Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers

Elizabeth L. Siegler, Xianhui Chen, Natnaree Siriwon et al. · Molecular Therapy · 2017 · 104 citations · Full text

, , +17

1–5 of 13